Lupin Limited has informed the Exchange regarding a press release dated February 12, 2026, titled "Lupin Q3 FY2026 Results".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin reported strong Q3 FY2026 results with consolidated sales of INR 71,005 Mn, up 26.4% year-on-year. EBITDA jumped 68.6% to INR 23,766 Mn with margins expanding 840 basis points to 33.5%. Profit after tax grew 37.4% YoY to INR 11,805 Mn, though it declined 20.5% sequentially due to one-time exceptional items of INR 4,266 Mn. US business delivered its highest-ever quarterly sales of USD 350 Mn (up 54% YoY), driven by 3 new product launches and 1 ANDA approval. India sales grew 5.6% and Emerging Markets surged 42.4%. The company maintains a net cash position of INR 28,793 Mn and invested 7.5% of sales in R&D.
Strong YoY growth across sales, EBITDA, and PAT signals healthy business momentum, particularly in the US market. However, the QoQ decline in PAT due to exceptional items may cause short-term volatility. The robust US performance, expanding margins, net cash balance sheet, and strong R&D pipeline (431 cumulative ANDA filings) are positive signals for long-term shareholders.